Ajuts a la recerca

Biomaterials for treatment and prevention of Alzheimer´s disease

Organisme

European Communities

Objecte

An estimated 7.3 million Europeans between 30 and 99 years of age suffered from different types of dementias in the EU27 in 2006 (14.6 per 1 000 inhabitants), most of these being of the Alzheimer’s variety. Innovative approaches based on biomaterials can improve the treatment and prevention of neurodegenerative disorders such as Alzheimer’s disease.

Proposals should develop new multifunctional biomaterials, as part of eventual Medical Devices and Advanced Therapies, which aim to create, optimise, enhance, substitute or support preventive and therapeutic interventions in Alzheimer’s disease. They can include: biocompatible and biodegradable biomaterials as part of minimally invasive treatments, theragnostic materials, and biocompatible materials that are easily degraded/cleared after completing their roles. The development of new drug candidates for Alzheimer’s and clinical trials are excluded.

The development of new integrated experimental and computational approaches aimed to describe interface processes and their determinants should be considered as the key step for the design of safe and performing materials. Experimental protocols should be planned taking due account of current good laboratory practice (GLP) and ISO guidelines. Standardisation and manufacturing processes can be addressed, including upscaling, good manufacturing practice (GMP), process analytical technology (PAT), and regulatory work in respect of relevant regulations as appropriate.

Termini oficial

* The official deadline for stage 1 is 26/03/2015

* The official deadline for stage 2 is 08/09/2015
 

Termini IISPV

IISPV's deadline: 02/10/2015 (europa@iispv.cat) Full proposal: IISPV's deadline: 03/16/2015

Pujar